Rezolute, Inc. Files 8-K with Financials

Ticker: RZLT · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1509261

Rezolute, Inc. 8-K Filing Summary
FieldDetail
CompanyRezolute, Inc. (RZLT)
Form Type8-K
Filed DateSep 2, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-disclosure, regulation-fd

TL;DR

Rezolute filed an 8-K on Sept 2nd, check financials.

AI Summary

Rezolute, Inc. filed an 8-K on September 2, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as AntriaBio, Inc., is incorporated in Nevada and headquartered in Redwood City, California.

Why It Matters

This filing provides updated information and financial disclosures for Rezolute, Inc., which is important for investors and stakeholders to assess the company's current status.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically contains standard corporate disclosures and financial information.

Key Players & Entities

  • Rezolute, Inc. (company) — Registrant
  • September 2, 2025 (date) — Date of earliest event reported
  • AntriaBio, Inc. (company) — Former company name
  • Nevada (jurisdiction) — State of incorporation
  • Redwood City, CA (location) — Address of Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, including disclosures under Regulation FD and financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on September 2, 2025.

What was Rezolute, Inc. formerly known as?

Rezolute, Inc. was formerly known as AntriaBio, Inc., with a name change date of January 14, 2013.

In which state is Rezolute, Inc. incorporated?

Rezolute, Inc. is incorporated in Nevada.

What is the business address of Rezolute, Inc.?

The business address of Rezolute, Inc. is 275 Shoreline Drive, Suite 500, Redwood City, CA 94065.

Filing Stats: 723 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2025-09-02 06:03:48

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share RZLT Nasdaq Capital Market

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On September 2, 2025, Rezolute, Inc. (the "Company") issued a press release to announce alignment with the FDA on design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism. In addition, the Company updated its corporate presentation to reflect updates to the upLIFT study. The information in this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K. The poster contains forward looking statements. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "prove," "potential," "seek," "strive," "try," or future or conditional verbs such as "predict," "could," "may," "likely," "should," "will," "would," or similar expressions. The Company's ability to predict results or the actual results of the Company's plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers of the poster are cautioned not to place undue reliance on these forward-looking cause such a difference include any other factors discussed in the Company

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated September 2, 2025 99.2 Corporate Presentation 104 Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REZOLUTE, INC. DATE: September 2, 2025 By: /s/ Nevan Charles Elam Nevan Charles Elam Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.